MX2021005210A - Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina. - Google Patents

Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.

Info

Publication number
MX2021005210A
MX2021005210A MX2021005210A MX2021005210A MX2021005210A MX 2021005210 A MX2021005210 A MX 2021005210A MX 2021005210 A MX2021005210 A MX 2021005210A MX 2021005210 A MX2021005210 A MX 2021005210A MX 2021005210 A MX2021005210 A MX 2021005210A
Authority
MX
Mexico
Prior art keywords
rosuvastatin
losartan
amlodipine
complex formulation
pharmaceutical
Prior art date
Application number
MX2021005210A
Other languages
English (en)
Inventor
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Ho Taek Im
Hyuk Jun Cho
Youngsu Yoon
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of MX2021005210A publication Critical patent/MX2021005210A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describe una composición farmacéutica para prevenir o tratar un trastorno cardiovascular que comprende amlodipino, rosuvastatina y losartán, y una formulación farmacéutica del complejo que comprende una primera parte de la mezcla que contiene amlodipino y rosuvastatina y una según parte de la mezcla que contiene losartán. La composición y formulación de complejo comprende rosuvastatina que tiene un tamaño de partícula (D90) de 50 µm o menos, y exhibe excelente velocidad de disolución, biodisponibilidad, estabilidad y uniformidad de contenido, y por lo tanto pueden ser útiles en industrias farmacéuticas.
MX2021005210A 2015-06-30 2017-11-08 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina. MX2021005210A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150093714 2015-06-30

Publications (1)

Publication Number Publication Date
MX2021005210A true MX2021005210A (es) 2021-06-18

Family

ID=57608904

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017014311A MX2017014311A (es) 2015-06-30 2016-06-29 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
MX2021005210A MX2021005210A (es) 2015-06-30 2017-11-08 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017014311A MX2017014311A (es) 2015-06-30 2016-06-29 Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.

Country Status (6)

Country Link
KR (2) KR20170003459A (es)
CN (2) CN108156807A (es)
MX (2) MX2017014311A (es)
PH (1) PH12017501986A1 (es)
RU (1) RU2724338C2 (es)
WO (1) WO2017003186A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019022436A2 (ko) * 2017-07-27 2019-01-31 에리슨제약(주) Nep 저해제 및 베타-차단제를 포함하는 약제학적 조성물
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
CN108245516B (zh) * 2017-11-09 2019-04-12 浙江京新药业股份有限公司 一种含瑞舒伐他汀钙的药物组合物及其制备方法
CN109464407A (zh) * 2018-12-27 2019-03-15 成都恒瑞制药有限公司 瑞舒伐他汀钙快速释放制剂及其制备方法
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
KR20220026641A (ko) * 2020-08-25 2022-03-07 주식회사 대웅제약 고혈압 및 고지혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100985254B1 (ko) * 2006-10-30 2010-10-04 한올바이오파마주식회사 방출성이 제어된 안지오텐신―Ⅱ―수용체 차단제와ＨＭＧ―ＣｏＡ 환원 효소 억제제의 복합 조성물
WO2009154810A2 (en) * 2008-02-25 2009-12-23 Dr. Reddy's Laboratories Ltd. Delivery systems for multiple active agents
EA020103B1 (ru) * 2009-01-23 2014-08-29 Ханми Сайенс Ко., Лтд. Твердая фармацевтическая композиция, содержащая амлодипин и лозартан, и способ ее получения
CN101690816A (zh) * 2009-08-16 2010-04-07 王丽燕 含钙拮抗剂、aⅱ受体拮抗剂和他汀类药的药物组合物
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
KR101910901B1 (ko) * 2013-11-29 2018-10-24 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제

Also Published As

Publication number Publication date
RU2724338C2 (ru) 2020-06-23
KR20180044873A (ko) 2018-05-03
PH12017501986A1 (en) 2018-03-19
RU2018103213A3 (es) 2019-12-09
KR20170003459A (ko) 2017-01-09
MX2017014311A (es) 2018-03-07
CN112933093A (zh) 2021-06-11
CN108156807A (zh) 2018-06-12
RU2018103213A (ru) 2019-07-31
WO2017003186A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
MX2021005210A (es) Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
PH12017500802A1 (en) Hydroxyalkyl-substituted phenyltriazole derivatives and uses thereof
MX2019000150A (es) Composiciones de microcapsulas estables.
TN2017000521A1 (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12016500833A1 (en) Pharmaceutical combination formulation comprising amlodipine, losartan and rosuvastatin
MA40241A (fr) Compositions enrichies stéréochimiquement pour l'administration d'acides nucléiques
MX2018006855A (es) Proceso de llenado en caliente con tapas hechas de composiciones de polietileno bimodales.
MX2018002863A (es) Recubrimiento en polvo y metodo para producir un recubrimiento en polvo.
EP3687540A4 (en) HETEROARYL COMPOUNDS USED AS CXCR4 INHIBITORS, COMPOSITION AND METHOD OF USE THEREOF
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
EP3626709A4 (en) INDAZOLE COMPOUND FOR USE IN INHIBITING KINASE ACTIVITY, COMPOSITION AND APPLICATION THEREOF
ZA201900421B (en) Novel quinazolinone derivatives inhibiting pi3k and pharmaceutical composition containing same
IL262020B (en) Grisiofulvin compound, preparations containing it and its uses
MX2018005349A (es) Articulos de vidrio con revestimientos de oxido de metal y polimero mezclados.
WO2017037276A8 (en) Polymers and microspheres
MX2018002595A (es) Mezclas biocidas.
HUP1500618A2 (en) Complexes of celecoxib and its salts and derivatives, process for the preparation thereof and pharmaceutical composition containing them
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
EP3611206A4 (en) MONOMER MIXTURE AND CURABLE COMPOSITION CONTAINING THE SAME
EP3547384A4 (en) HIGH POLYMER, MIXTURE THEREOF, COMPOSITION, ORGANIC ELECTRONIC COMPONENT AND MONOMER FOR POLYMERIZATION
EP3545049A4 (en) LUMINESCENT TRACE COMPOSITIONS, LUMINESCENT SUBSTANCES COMPRISING SAME, AND ARTICLES COMPRISING SAME
PH12017500536A1 (en) Solid pharmaceutical composition comprising amlodipine and losartan
EP3398608A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER OR CANCER METASTASES WITH PSTL1-PRTEIN AS AN ACTIVE SUBSTANCE
EP3608669A4 (en) FLUORESCENT PRE-MIXED PARTICLES, FLUORESCENT STYLING THEREFOR, AND FLUORESCENT STYLING METHOD WHICH ARE USED THEREOF
WO2017120098A8 (en) Stimuli-responsive polymeric nanoparticles, methods of making stimuli-responsive polymeric nanoparticles, and methods of using stimuli-responsive polymeric nanoparticles